The $2.4 million grant, which was awarded to a Crucell-led consortium of six leading European Universities and companies in the field of malaria research, will finance preclinical studies toward an affordable, safe and efficacious two-component pediatric malaria vaccine.
Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market.
“The grant will go a long way toward streamlining Crucell's focus on the fundamental global needs for a much-needed malaria vaccine,” said Dr Jaap Goudsmit, Crucell's chief scientific officer.